Troxacitabine (Shire Pharmaceuticals).
Shire Pharmaceuticals (formerly BioChem Pharma) is developing troxacitabine (Troxatyl), a novel dioxolane nucleoside analog, as a potential treatment for acute myeloid leukemia (AML), pancreatic cancer and solid tumors. Phase I and II clinical studies in patients with pancreatic cancer and AML are in progress.
Ecker
Gerhard
G
Institute of Pharmaceutical Chemistry, University of Vienna, Austria. Gerhard.F.Ecker@univie.ac.at
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003596:Cytosine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004148:Dioxolanes / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D004148:Dioxolanes; C074908:troxacitabine; D003596:Cytosine